Ischemic stroke remains a significant risk for patients with atrial fibrillation (AF). The Food and Drug Administration (FDA) approval of the WATCHMAN device for percutaneous closure of the left atrial appendage (LAA) represents an important addition to the physician's armamentarium to help mitigate this problem. The evolution of LAA occlusion technology has spanned nearly two decades and three FDA panel hearings, leading to FDA approval in 2015. As this technology becomes clinically available to a broader population of patients, it is essential that physician stakeholders establish criteria for the performance of these procedures that will be used in granting initial and ongoing privileges. These criteria are offered to support The Joint Commission mandate that medical staff privileges be granted on the basis of professional criteria specified in the medical staff bylaws to ensure safe and effective patient-centered care. The emergence of transcatheter valve therapies has provided a model whereby multiple societies collaborate to provide recommendations to institutions and operators to assess their potential to establish and maintain programs for these therapies (1-3). As an extension of this concept, the Society of Cardiovascular Angiography and Interventions (SCAI), the Heart Rhythm Society (HRS), and the American College of Cardiology (ACC) agreed to provide recommendations to institutions and interested physicians for the establishment and maintenance of LAA occlusion programs.
I. Preamble
Ischemic stroke remains a significant risk for patients with atrial fibrillation (AF). The Food and Drug Administration (FDA) approval of the WATCHMAN device for percutaneous closure of the left atrial appendage (LAA) represents an important addition to the physician's armamentarium to help mitigate this problem. The evolution of LAA occlusion technology has spanned nearly two decades and three FDA panel hearings, leading to FDA approval in 2015. As this technology becomes clinically available to a broader population of patients, it is essential that physician stakeholders establish criteria for the performance of these procedures that will be used in granting initial and ongoing privileges. These criteria are offered to support The Joint Commission mandate that medical staff privileges be granted on the basis of professional criteria specified in the medical staff bylaws to ensure safe and effective patient-centered care. The emergence of transcatheter valve therapies has provided a model whereby multiple societies collaborate to provide recommendations to institutions and operators to assess their potential to establish and maintain programs for these therapies (1) (2) (3) . As an extension of this concept, the Society of Cardiovascular Angiography and Interventions (SCAI), the Heart Rhythm Society (HRS), and the American College of Cardiology (ACC) agreed to provide recommendations to institutions and interested physicians for the establishment and maintenance of LAA occlusion programs.
An initial multi-society overview of the field of LAA occlusion has recently been published, highlighting the critical issues surrounding LAA occlusion therapies (4) . This document states that the questions of who should perform these procedures and the institutional support required need further delineation. It is these issues that are the subject of this, the second multi-society document. As LAA occlusion is in its early developmental stages, the recommendations must initially rely on expert consensus. As experience with LAA occlusion grows, these recommendations will be revised and updated based on expanded expertise and published data. However, the recent FDA approval of the first percutaneous LAA occlusion device underscores the need to make initial recommendations now; this will provide a starting point for future modifications. The recommendations that follow were reviewed by the entire writing committee, with at least 70% concurrence required in order to be incorporated.
In accordance with the partnering societies' policies on relationships with industry and other entities (RWI), relevant author disclosures are included in Appendix 1. In addition, authors' comprehensive RWI information, which includes RWI not relevant to this document, is available online as a data supplement programs must work together in the context of a larger system of health that includes stakeholders from multiple disciplines with overlapping skillsets. The notion of multidisciplinary teams was first validated in the surgical arena and has gained traction more recently with the evolution of percutaneous valve therapies (1, 3, 14, 15) . It is therefore expected that stroke prevention in AF in general, and LAA occlusion in particular, will be a collaborative effort of physician and non-physician experts that may include electrophysiologists, interventional cardiologists, neurologists, imaging experts, primary care providers, cardiac surgeons, and others.
III. Background
Although large randomized clinical trials have demonstrated the efficacy of oral anticoagulant therapy in lowering the risk of stroke and death in patients with AF, the main obstacle to long-term anticoagulant use is major bleeding, which has an incidence of 2%-4%/year (5, 6, 7) . The traditional anticoagulant, warfarin, is hampered by a narrow therapeutic window, a need for frequent blood testing, and dietary restrictions leading to patient non-compliance. Novel anticoagulants partially address these issues but are still limited by bleeding and noncompliance (16) (17) (18) (19) . Although complete elimination of AF would be an attractive alternative strategy in theory, contemporary pharmacologic or invasive radiofrequency ablative therapies have not been shown to reduce stroke risk or to prevent the need for long-term anticoagulant therapy (7, 20) . The observation that >90%
of thrombi identified in patients with non-valvular AF are found in the LAA has led to the development of mechanical approaches to closing the LAA orifice (21) . Several percutaneous approaches to LAA occlusion have been developed through multiple pathways, including the off-label use of FDA-approved devices (LARIAT and atrial or ventricular septal defect closure devices), the use of devices for LAA occlusion available in other countries through their regulatory pathways, and the FDA pivotal trial pathway for class III medical devices (8, 22) . Only one such device to date, the WATCHMAN, has received FDA approval for this indication. It is anticipated that this field will grow and the armamentarium of devices for this application will expand. Therefore, it is essential that stakeholders have a thorough understanding of the cognitive and technical aspects surrounding LAA occlusion in general and the various technologies for LAA occlusion currently available and in development.
IV. Cognitive Requirements
Percutaneous LAA occlusion is a new technique, and a significant learning curve for deployment of the WATCHMAN device has demonstrated reduced procedure time, Prior to performing percutaneous LAA occlusion procedures, physicians should have a detailed understanding of the regional anatomy of the heart, including the left atrium and LAA. Knowledge of, and appropriate experience with, transseptal puncture techniques through an intact septum and manipulation of sheaths and catheters within the left atrium, particularly in the context of complex anatomy, are critical (see Table I ).
Experience with specific procedures requiring access to the left side of the heart is important. These procedures may include:
 LAA occlusion involving a transseptal catheterization that may be primary 
V. Procedural Skills and Operator Requirements
There are several devices and approaches for minimally invasive LAA closure (both endocardial and epicardial) at various stages of development (8) . In the coming years, these devices and others will probably be available for clinical use in the United States.
While there are common principles, each different device technology will also have unique skillsets to be mastered. The number of procedures required for an operator to become fully competent to perform a procedure and those required to maintain competence will vary depending on the complexity of the system being used, operator experience, and an operator's technical and cognitive strengths and weaknesses. Currently, there are no publications establishing data specific to the challenges of LAA occlusion. SCAI has surveyed structural heart program training directors to elicit opinions on the minimum numbers of procedures required to obtain competency for a variety of complex procedures (24) . Most pertinent to LAA occlusion would be transseptal puncture through an intact septum, the average recommended number for which falls in the range of 20-25 per year (25) . Similarly, the electrophysiology literature suggests that complications associated with left-sided ablation of AF (requiring transseptal puncture) decrease after 25
procedures (23, 26) . Given the limitations of the available data, the writing committee arrived at consensus recommendations for operator requirements for LAA occlusion, which are summarized in Table I .
Operator Skill Sets
As mentioned earlier, each device has unique characteristics that necessitate a consistent, therapy, are potential populations that may benefit from this technology and should be studied (27) .
Vascular Access and Transseptal Puncture
Fundamental aspects of obtaining vascular access, working with long wires and sheaths, the use of fluoroscopy and contrast agents, and closed loop hemodynamic monitoring systems would be expected to be part of the foundational knowledge base of interventional and invasive electrophysiology training programs, representing level II and III COCATS milestones (24-36 months of training) (23, 25, 28) . Given the risks associated with transseptal puncture and the importance of being able to accurately localize the puncture site within the interatrial septum, it is expected that operators will be well trained in transseptal puncture before endeavoring to perform LAA occlusion. Alternatively, this skillset may be acquired specifically in the context of performing LAA occlusion under supervision in a high-volume training center with direct participation by an operator experienced in transseptal puncture. The prospective WATCHMAN studies were carried out by procedural specialists who had been performing transseptal puncture "routinely,"
where "routinely" had no specific definition (9) . It is the writing committee's consensus opinion that new operators should have performed 50 lifetime de novo left-sided structural or ablation procedures, 25 of which have involve transseptal puncture through an intact septum and should, on an ongoing basis to maintain proficiency, perform at least 25 transseptal punctures over a two-year period, 12 of which are LAA occlusion procedures (> 1 per month) ( Table I ). In the case of physician teams composed of two operators, at least one of the physicians will be required to meet the qualifying and ongoing proficiency requirements.
It is critical that the procedural specialist employ a standardized, consistent It is important for appendage plug-design closure systems that the implanter has sufficient control and anatomical understanding to place the transseptal puncture at a site that will ideally align the delivery apparatus with the LAA. Typically, this site is posterior and inferior, although the location will vary depending on the relative height and orientation of the LAA ostium and size of the atria. The implanter needs to understand echocardiographic imaging techniques in order to make this determination with precision. If the procedural specialist relies on TEE guidance for transseptal puncture, familiarity with imaging of the interatrial septum (IAS) in multiple planes to identify the ideal septal target is important.
Optimal imaging of the LAA itself typically requires TEE or ICE guidance. However, ICE has not been systematically investigated in terms of its adequacy for LAA imaging for the implant phase of this procedure and is not widely used for this purpose.
Management of Sheaths and Device Delivery in the Left Atrium
Most devices require transseptal wire exchange for a large bore outer diameter sheath.
While there are variations in sheath design, there are fundamental practices with which the operator must be adept. Meticulous attention to avoid emboli, either air or thrombus, is a central theme for sheath manipulation since intraprocedural embolic events had significant impact during the learning curve of the PROTECT AF Trial (9) . Once the device delivery sheath is in place, operators need to understand the relationship between the sheath and the LAA, atrial roof, pulmonary veins, and posterior atrial wall at all times, as these are all thin-walled structures prone to perforation.
It is usual practice to perform large bore sheath exchanges over a stiff 0.035" guidewire positioned in the left upper pulmonary vein. A pigtail catheter is generally used to position the delivery sheath in the LAA; the depth required for sheath placement will vary depending on device design. With the current WATCHMAN device, it is necessary to advance the sheath fully, through most of the depth of the LAA, and the use of a pigtail catheter provides an extra measure of safety against perforation. This practice became common as PROTECT AF enrollment progressed, and it may have contributed to the marked decrease in pericardial effusions during the course of the PROTECT AF Trial.
Subsequent adoption of this technique may explain in part why new operators had a low (<1%) incidence of tamponade complicating the implants (11).
The LAA is often a multilobar structure, and operators must be able to formulate a 3-D image for proper execution of the procedure. This spatial image of LAA anatomy, largely derived from 2-dimensional imaging data, or increasingly from 3D echo, is used to guide structural heart disease interventions. Assessment of the adequacy of closure must take into account the volume status of the patient at the time of the implant, the true number of lobes requiring closure, an understanding of the ideal sheath curve for a given anatomy, and the motion path of the sheath system in response to clockwise and counterclockwise torqueing.
Management of Complications
The most common potentially serious complication associated with LAA occlusion is pericardial effusion and tamponade. This complication can occur acutely (early) or occasionally insidiously (weeks) following implant (9, 29) . There should be a structured program for post-discharge follow up and evaluation by a cardiovascular specialist.
VI. Institutional Requirements
An overview of the institutional requirements to perform percutaneous LAA occlusion has been provided by a recent societal overview co-authored by SCAI, HRS, and ACC (4). The institution should have an established structural heart disease (SHD) and/or electrophysiology (EP) program, as well as the physical space and ancillary services to execute the procedure effectively and safely. Specifically, the writing committee considered the following aspects to be key institutional requirements:
Institutional volume
An aggregate of 50 structural heart disease or left-sided catheter ablations, at least 25 of which involve transseptal puncture through an intact septum, should be performed at the institution in the year leading to starting an LAA occlusion program and per year thereafter (see Table I for qualifying left-sided procedures).
The rationale is that not only the primary procedural specialist or physician team, but also ancillary staff, should be comfortable with the basic aspects of the procedure. c. Mobile C-Arm for fluoroscopic imaging is not acceptable.
d. Biplane imaging is helpful but not required.
e. The room should be adequately sized to accommodate echocardiographic and anesthesia equipment, in addition to the regular radiographic imaging system.
f. The interventional suite should be stocked with equipment for safe procedures and for handling complications such as device stabilization, retrieval, and managing pericardial effusions. This equipment includes a variety of endovascular sheaths, diagnostic catheters, transseptal kits, wires, snares, bioptomes, vascular occluders, and pericardiocentesis equipment.
g. Cell-Saver technology for rapid processing of drained blood and re-transfusion in case of pericardial effusion and tamponade should be readily available.
Echocardiography
a. An echocardiography laboratory with the full array of transthoracic and TEE capabilities should be on site.
b. A TEE-capable machine and probe should be available in the procedure room.
c. Appropriate staff should be present during the procedure, which may include a cardiologist or cardiac anesthesiologist familiar with the procedural steps and subtleties of invasive echocardiography.
d. Three-dimensional echocardiography capability is helpful but not required.
Ancillary services a. Multidisciplinary team/Outpatient clinic
Optimally, an LAA occlusion program should be embedded in a comprehensive AF and structural heart program to allow for comprehensive patient care. The composition of the MDT caring for the patient will vary from site to site. In addition to an electrophysiologist and/or interventional cardiologist (pediatric or adult) or cardiovascular surgeon fully trained in SHD procedures, who will be the primary operator(s) for the procedure, physicians with expertise in procedure-guided TEE, ICE, or management of AF should be available. The composition of the implanting team will vary from center to center. In some institutions, physician teams, consisting of a primary operator along with an assistant or co-operator, may jointly perform the procedure to offer the greatest expertise and to optimize procedural success and safety. In other highly experienced centers, a single procedural specialist may be adequate for device implantation. Physician specialists and technologists skilled in CT and other imaging modality interpretation should be available if procedures that require CT imaging are performed. In addition, a non-physician provider (nurse, nurse practitioner, physician assistant) could be helpful in facilitating the MDT approach.
b. Cardiac surgery
A cardiac surgeon, anesthesiologist, and perfusionist should be on site for surgical backup. Cardiac surgery operating rooms should be readily available in the rare event of a major complication requiring surgical intervention.
c. Post-procedural care
After undergoing LAA occlusion, patients can be managed in a post-anesthesia care unit, intensive care unit, or telemetry unit. Personnel experienced in managing patients undergoing complex cardiac procedures must be present.
d. Blood bank
A blood bank does not have to be on site; however, it is prudent that patients be typed and screened, with packed red-blood cells available if needed.
VII. Training Models
Effective and efficient acquisition of the technical skills for LAA occlusion can be highly 
VIII. Quality Assessment
The objective of LAA occlusion is to achieve as complete and proximal a closure of the appendage as possible while maintaining patient safety. Quality measures must be established that evaluate both of these issues over time. 
Registry

Individual Institutions
Although participation in a registry will likely be mandatory for use of the currently approved device, it is important for individual institutions to have aggregate and operatorspecific quality analysis processes. Within institutions, a regular quality analysis process reviewing key metrics, including numbers of implants, complications, and outcomes, should be a standard part of any LAA occlusion program.
After LAA occlusion, results from continued follow-up and the new enrollment study, along with an analysis of national databases, would be beneficial for measuring initial and long-term clinical outcomes. However, individual institutions should have protocols in place for follow-up that include echocardiographic and other imaging data that identify the presence and severity of persistent leaks; medication use (particularly anticoagulants); and clinical outcomes, including bleeding, neurologic events, and device complications. surgeons. This document uses the term "procedural specialist" to apply to members of any subspecialty who implant LAA occlusion devices. In some cases, a physician team will be composed of two operators; therefore, the procedural volume criteria and ongoing proficiency requirements apply to at least one member of the team. **LAA occlusion involving a transseptal catheterization that is primary (i.e., WATCHMAN or similar devices) or adjunctive to a percutaneous pericardial approach (i.e., LARIAT), percutaneous left ventricular assist device placement when such devices involve transseptal approach (i.e. Tandem Heart), endovascular catheter ablation within the left side of the heart, pulmonary vein stenting, balloon mitral valvuloplasty, percutaneous closure of prosthetic mitral paravalvular leaks using a transseptal approach, antegrade balloon aortic valvuloplasty, mitral valve repair using the MitraClip system or other technique involving transseptal puncture, ASD or PFO closure, and diagnostic transseptal catheterization.
